Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arcutis Biotherapeutics Inc
(NQ:
ARQT
)
9.480
+0.130 (+1.39%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Arcutis Biotherapeutics Inc
< Previous
1
2
3
4
Next >
7 Short-Interest Stocks to Target for Explosive Gains
May 18, 2023
For contrarian investors that can stand the heat, short-interest stocks to buy can offer significant rewards in a short time period.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
May 18, 2023
Via
Benzinga
The Latest Analyst Ratings for Arcutis Biotherapeutics
May 17, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
May 10, 2023
Via
Benzinga
Arcutis Biotherapeutics: Q1 Earnings Insights
May 09, 2023
Via
Benzinga
Global Payments, MGM Resorts And 3 Stocks To Watch Heading Into Monday
May 01, 2023
With US stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
Where Arcutis Biotherapeutics Stands With Analysts
March 29, 2023
Via
Benzinga
Arcutis Biotherapeutics's Earnings Outlook
February 27, 2023
Via
Benzinga
Arcutis Shares Gain On Positive Phase 3 Data On Roflumilast Foam In Scalp, Body Psoriasis
September 26, 2022
Via
Benzinga
Arcutis' Flagship Psoriasis Treatment Shows Sustained Efficacy, Clearance For Median Of 10 Months
January 17, 2023
Via
Benzinga
Arcutis Biotherapeutics Stock Surges After Successful Atopic Dermatitis Trial
November 15, 2022
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) announced topline results from its INTEGUMENT-1 pivotal Phase 3 trial of roflumilast cream 0.15% for mild to moderate atopic dermatitis.
Via
Benzinga
Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing
November 09, 2022
Biotech stocks were hammered Wednesday, including several that had good news.
Via
Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
October 21, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
What 4 Analyst Ratings Have To Say About Arcutis Biotherapeutics
September 22, 2022
Over the past 3 months, 4 analysts have published their opinion on Arcutis Biotherapeutics (NASDAQ:ARQT) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Atopic Dermatitis Player Arcutis Scoops Up DucentisBioTherapeutics
September 08, 2022
Via
Benzinga
Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary
September 09, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022
September 07, 2022
Upgrades
Via
Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 23, 2022
Via
Benzinga
Why PolyPid Dipped Over 73%; Here Are 60 Biggest Movers From Friday
September 06, 2022
Gainers Venus Concept Inc. (NASDAQ: VERO) jumped 54.9% to settle at $0.5419 on Friday. The company, last month, posted downbeat quarterly results.
Via
Benzinga
Arcutis Concludes Dosing In Late-Stage Itchy Skin Study, Anticipates Regulatory Submission By Next Year
August 23, 2022
Arcutis Biotherapeutics (NASDAQ: ARQT) has completed the enrollment of subject in its INTEGUMENT-2 pivotal Phase 3 trial of roflumilast cream 0.15% in adults and children with Atopic dermatitis (AD).
Via
Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
August 04, 2022
The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients...
Via
Benzinga
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
August 04, 2022
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume.
Via
Benzinga
Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session
August 03, 2022
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday.
Via
Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
August 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Analyst Ratings for Arcutis Biotherapeutics
August 02, 2022
Over the past 3 months, 4 analysts have published their opinion on Arcutis Biotherapeutics (NASDAQ:ARQT) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
August 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday
August 02, 2022
Gainers Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around 18% on Friday.
Via
Benzinga
Recap Of Friday's Biotech Catalysts - End of The Day Summary
July 29, 2022
Via
Benzinga
Arcutis Gets FDA Nod For Plaque Psoriasis Candidate, Sees Commercial Launch In Mid-August
July 29, 2022
The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ: ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in...
Via
Benzinga
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update
July 29, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.